Skip to main content

Health Care Enforcement Year in Review & 2021 Outlook

Mintz

Feb
24
2021

Date: February 24, 2021

Time: 1:00PM - 2:00PM (EST)

Location: Webinar

Despite the threat of COVID-19 paralyzing much of the country in 2020, government health care fraud enforcement continued even though the Department of Justice (DOJ) had the added burden of pursuing COVID-19 related fraud. While criminal enforcement actions involving opioids remained a top enforcement priority, the civil False Claims Act (FCA) is still one of the government’s most powerful enforcement tools. In our annual webinar, Mintz’s Health Care Enforcement Defense team will review the key policy developments, settlements, and court decisions from 2020 and assess their likely impact in 2021 and beyond.

Topics will include:

  • Statistical analysis of trends in qui tam litigation in 2020
  • Examination of DOJ’s health care fraud enforcement priorities  in 2020, including opioids, genetic testing, telemedicine, risk adjustment, and elder abuse
  • Review of COVID-19 related fraud in 2020 and the possible shift toward increased civil investigations in this area in 2021
  • Overview of new federal agency guidance and actions in 2020
  • Outlook on regulatory and enforcement activity in 2021 under the Biden administration and anticipated targets, including pharmacies, consulting firms, EHR vendors, laboratories, and Medicare Advantage plans

For a deeper dive into these topics please read the accompanying report: Mintz's Health Care Enforcement 2020 Year in Review & 2021 Outlook. 

Speakers

Professional_Cropped_Foster_Hope_Mintz

Hope S. Foster

Moderator

Hope regularly defends health care companies in governmental investigations and ensuing cases, conducts internal investigations, and advises providers and manufacturers regarding enforcement issues.
Eoin Beirne Headshot

Eoin P. Beirne

Speaker

Eóin P. Beirne is co-chair of Mintz’s White Collar Defense and Government Investigations group. He guides clients from a wide range of industries through federal and state investigations and enforcement proceedings.

Speaker

Karen advises industry clients on regulatory, transactional, operational, and enforcement matters. She has deep experience handling FCA investigations and qui tam litigation for laboratories and diagnostics companies.